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doi:10.1016/j.jfma.2012.02.024Positron emission tomography (PET), magnetic resonance imaging (MRI), and integrated 18-
fluorodeoxyglucose (18F-FDG) PET/computed tomography are valuable techniques for assessing
prognosis, treatment response after the completion of concurrent chemoradiation, suspicious
or documented recurrence, unexplained post therapy elevations in tumor markers, and the
response to salvage treatment when managing cervical cancer. However, PET plays a limited
role in the primary staging of MRI-defined node-negative patients. Currently, 18F-FDG is still
the only tracer approved for routine use, but several novel targeting PET compounds, high-
Tesla MRI machines, diffusion-weighted imaging without contrast, and dynamic nuclear
polarized-enhanced 13C-MR spectroscopic imaging may hold promising applications.
Copyright ª 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Introduction
Worldwide, cervical cancer is the third most common form
of cancer that afflicts women and the fourth highest cause
of cancer mortality in women.1 Early-stage cervical cancert of Obstetrics and Gyne-
l, 5 Fu-Shin Street, Kueishan,
et.net (C.-H. Lai).
ight ª 2012, Elsevier Taiwan LLC(IA2eIIA1 according to the 2009 International Federation of
Gynecology and Obstetrics [FIGO] staging criteria2) can be
cured by either radical surgery or radiotherapy, while
patients with stage IA1eIB1 can be treated with fertility-
preserving surgery. Generally, stage IB2eIV (except IIA1)
cancer can be treated with definitive radiation with
concurrent platinum-based chemotherapy.1,3 Accurate
clinical staging is crucial for the selection of primary
therapy in order to achieve the highest survival rate with
the lowest morbidity.& Formosan Medical Association. All rights reserved.
Molecular imaging in cervical cancer 413Nodal metastasis is an independent prognostic factor in
cervical cancer patients who are being treated with primary
radical surgery4 or radiotherapy.5 Because advanced
imaging technologies are not available in many countries
where cervical cancer is prevalent, the FIGO staging system
does not consider pelvic (PLN) or para-aortic lymph nodes
(PALN) in the staging criteria for the uniform classification of
tumor extent or the comparison of clinical results. FIGO and
the National Comprehensive Cancer Network (NCCN) prac-
tice guidelines for oncology both advocate the use of
imaging methods to define tumor extent when planning
treatment options for individual patients.2,3 Computed
tomography (CT) or conventional magnetic resonance
imaging (MRI) have been determined by the American
College of Radiology Imaging Network and Gynecologic
Oncology Group (ACRIN/GOG) to be suboptimal for evalu-
ating the depth of cervical stromal invasion, PLNmetastasis,
parametrial extension, and visualizing primary tumors.6,7
Positron emission tomography (PET) is a molecular imaging
technique that uses radiolabeled molecules to visualize
molecules, cells, and biological processes in living organisms
and humans. The most commonly used radiotracer in clinical
practice and for the study of malignant tumors is 18-
fluorodeoxyglucose (18F-FDG). 18F-FDG is actively taken up
at the cellular level by glucose transporters, then phosphor-
ylated and no longer metabolized. Therefore, it remains
trapped within the cell. 18F-FDG-PET is very highly sensitivity
for the detection of > 90% of cancers during staging and
restagingandforassessing thetherapeutic responseonfollow-
upexaminations.8,9 In cervical cancer, radiotracers other than
18F-FDG, such as 11C-choline,10 60Cu- or 64Cu-labeled diacetyl-
bis(N4-methylthiosemicarbazone) (64Cu-ATSM), have been
successfully applied in humans to diagnose hypoxia.11,12 18F-
FDG is still the only tracer approved for routine clinical use.9
This review summarizes recent developments in the use
of molecular imaging technology in oncological applications
and the use of MRI and 18F-FDG PET in the management of
cervical cancer.
Recent advances in molecular imaging
technologies
PET imaging
Although FDG is widely used in clinical applications, not all
tumors show a significant increase in metabolic activity on
FDG-PET imaging. In particular, prostate cancer, neuroen-
docrine tumors, and hepatic tumors may be virtually
invisible on PET. Furthermore, with FDG it is difficult to
evaluate malignant lesions in tissues that physiologically
take up FDG (such as the central nervous system) or excrete
FDG (such as the kidneys and bladder) or differentiate
between inflammation and cancer. Therefore, in addition
to FDG, several other tracers have been proposed.
The use of targeted therapeutics has challenged the
notion of how imaging techniques assess tumor response to
treatment because many new agents are thought to cause
cytostasis rather than cytotoxicity. Currently, targeting PET
compounds have been developed for oncological studies,
but even though tumor size estimation might not correlate
well with the true tumor response, PET has merged as themost sensitive imaging tool for the metabolic profiling of
individual tumors.9 These compounds include 11C-acetate
(a precursor of membrane fatty acids), 11C-methionine (a
precursor of S-adenosylmethionine, which is required for
polyamine synthesis), 18F-choline (a substrate of choline
kinase in choline metabolism), and 18F-3’-fluoro-3’-deoxy-
L-thymidine (18F-FLT) (a substrate of thymidine kinase [TK-
2] in DNA synthesis, a specific marker of cell proliferation).
For the evaluation of specific types of tissues or tumors,
several PETcompounds havebeenused in clinical trials, either
for inclusion criteria or as an endpoint. These include 18F-
fluoride (which incorporates into the hydroxyapatite crystals
of bone), 18F-3,4-dihydroxyphenylalanine (DOPA) (which is
involved in amino acid transport and protein synthesis in
neuroendocrine tumors13), 68Ga-(tetra-aza-cyclododecane-N
N’N’’N-’’’-tetra-acetate-[Tyr]-octreotide) DOTA-TOC/-DOTA-
(-1-Nal3-octreotide) NOC (somatostatin analogues, receptor
binding [somatostatin receptor type 2 gene (SSTR-II), -V] in
neuroendocrine tumors), 16-a-[18F]fluoro-17-b-estradiol (FES)
(a specific estrogen-binding receptor involved in breast
cancer), 18F-Annexin-V (specifically binds to phosphatidylser-
ine on cell membranes during apoptosis), 18F-FLT (involved in
cell proliferation14), 18F-RGD-K5 (integrin receptors [avb3] are
present on endothelial cells during neovasculogenesis and
angiogenesis15), 18F-MISO, 64Cu-ATSM, 18F-EF5 (involved in
intracellular reduction, binding, and hypoxia), and immuno-
PET with 124I-G250 (used to identify the tumor type when
deciding the appropriate therapy for renal cell carcinoma).16
Magnetic resonance imaging
Important advances in MRI have taken place in oncology in
recent years. In combination with newly developed pulse
sequences, perfusion or dynamic contrast-enhanced perfu-
sion-weighted MRI (DCE-PWI) techniques, and diffusion-
weighted imaging (DWI), MR imaging has been proven to
play a better role in evaluating cervical cancer than
conventional MRI.17,18 Newly developed techniques such as
dynamic nuclear polarized (DNP)-enhanced 13C-magnetic
resonance spectroscopic imaging (DNP-MRSI), abdominal
susceptibility-weighted imaging (SWI), MR imaging, and MR/
PETare exciting fields of research. Future applications of MRI
are expected to utilize DNP-MRI by using hyperpolarized
gases (e.g., 13C and 3He) as contrast agents, which enables
MRSI to have 10,000-times the signal-to-noise ratio in
comparison to conventional MRI. The technique has been
used to image 13C-containing metabolites in tumors
(including prostate tumors), cardiac tissue, and the brain.19
The future applications of MRI will focus on hyper-
polarized DNP-MRSI, DW-MRI, MR/PET,19 and target-
contrasted MR lymphography,20 which are probably the
most promising trends in gynecological-oncological evalu-
ations and management in the near future.Roles of PET in primary staging, response
evaluation, detection, and the management of
recurrence
Showalter found that tumor diameters estimated using
18F-FDG-PET (referred to as simply PET hereafter) were
414 C.-H. Lai et al.correlated with the pathological tumor diameters of the
surgical specimens with a correlation coefficient of 0.757 (p
< 0.0001).21 PET and integrated PET/CT are valuable tools
for assessing prognosis22e24and primary staging,23e32 the
determination of the treatment goal (curative or palliative)
in patients with PALN31 or SLN32 metastasis as detected by
CT/MRI (Table 1 23e32) and the treatment response after the
completion of concurrent chemoradiation,33 and doc-
umenting recurrent cervical cancer,34 unexplained post-
treatment elevations in tumor markers,35 and follow-up
after salvage therapy.36 An early study demonstrated the
significant sensitivity of PET for detecting PLN metastasis
over MRI.37 Goyal et al reported that using PET/CT alone
could avoid multimodality therapy for the treatment of
operable stage IB1eIIA1 cervical cancer.38 Chou et al
showed that PET provides significantly better diagnostic
efficacy than MRI for detecting PALN metastasis and that
the standardized uptake value (SUV)max of primary cervical
tumors > 5.3 is an independent and poor prognostic factor
in stage IeIIB cervical adenocarcinoma and adenosquamous
carcinoma.39
In contrast, the same group found that PET plays
a limited role in the primary staging of MRI-defined node-
negative stage IeII patients.40 Ryu et al41 used PET in
routine posttherapy surveillance (n Z 249) and found that
among 80 patients with positive PET scans, only 28
demonstrated confirmed recurrence (false-positive rate of
65%). When Havrilesky et al42 used PET to evaluate clini-
cally suspicious recurrence, the positive predictive value
was 85.7% (Table 2).6,34e38,40e42,47,48 A randomized
controlled study on the use of PET to evaluate MRI-defined
pelvic node-positive patients prior to chemoradiation did
not show a significant survival benefit of using additional
PET arm, which reflects the importance of cost-effective
research on molecular imaging tools.28 Schwarz et al
found PET/CT to be useful for monitoring treatment
responses during concurrent chemoradiation.43 The role of
using PET with FDG or other novel targeted radiopharma-
ceuticals for predicting or monitoring the response will
become more important in the future.44Roles of MRI in differential diagnosis, staging,
and response assessment
Patients with a histological diagnosis of adenocarcinoma or
adenosquamous carcinoma by cervical biopsy should be
differentially diagnosed as cervical or endometrial origin
because the treatment strategies for these two sites are
different. Vagas et al showed that when two radiologists
were independently and retrospectively asked to deter-
mine the tumor origin from MRI studies of 48 patients (32
endometrial and 16 cervical cases), and the odds ratios of
the tumor originating from the site were 4.80e6.35 greater
than they would have been if no other information was
available.45 Rockall et al46 used nanoparticle-enhanced MRI
to evaluate 29 cervical cancer patients using ultrasmall
particles of iron oxide (USPIO) followed by lymphadenec-
tomy. The sensitivity (SN) of detecting LN metastasis was
significantly better using USPIO (93%) compared with using
size criteria alone (29%) on a nodal basis. Hori et al
compared 3-Tesla (3T) versus 1.5T MR without DWI andfound a significantly better signal-to-noise ratio and mean
tumor-to-cervical contrast-to-noise ratios using 3T MR in
comparison with 1.5T MR, but the LN metastasis detection
efficacies were similar.47
Lin et al48 used 3T MRI with DWI, fusion, and T2-weighted
imaging. The combination of size and apparent diffusion
coefficient (ADC) differences (3T MRI with DWI) resulted in
better sensitivity (25% vs. 83%) and similar specificities (98%
vs. 99%) for the diagnosis of LNmetastasis in comparisonwith
conventional MRI (Table 2). A French study using 1.5TMRI and
DWI at 8 weeks (range: 4e20 weeks) indicated residual
tumors after radiotherapy/concurrent chemoradiation (RT/
CCRT).49 The mean ADC was 1.62  0.21  10-3 mm2/second
(standard deviation [SD] Z 1.45  10-4 mm2/second) for
those with residual disease (nZ 5) versus 1.76  0.33  10-
3 mm2/second (SDZ 1.99 10-4 mm2/second) for those with
complete remission (CR) (nZ 44; pZ 0.09). Using 1.7  10-
3 mm2/second as a cut-off value for the mean ADC, all
patients with histologically proven residual disease had
a value  1.7  10-3 mm2/second.49Comparisons between different imaging
modalities
Ho et al50 investigated the correlation between ADCs
measured using 3T MRI with DWI and SUV from PET in 33
patients with primary cervical cancer. The relative ADCmin
(rADCmin) was defined as the ratio between ADCmin/ADCmean
and was found to be significantly and inversely correlated
with the relative SUVmax (rSUVmax) as defined by the ratio
between SUVmax/SUVmean (r Z -0.526, p Z 0.0017).
A significant inverse correlation between rADCmin and
rSUVmax was observed between patients with adenocarci-
noma and adenosquamous carcinoma (r Z -0.685,
p Z 0.0012) and those with well- to moderately differen-
tiated tumors (r Z -0.631, p Z 0.0050).50 A prospective
study evaluated the use of lymphangiography, CT/MRI, and
PET imaging for the detection of lymph node metastasis in
patients receiving primary chemoradiotherapy for cervical
cancer.51 Agreement between imaging was most consistent
in the common iliac LN (p < 0.001) and the least consistent
in the PALN (p Z 0.41). Disease-free and overall survival
rates were most accurately predicted by PET.51 A Korean
retrospective study (n Z 83) reviewed patients with
cervical cancer who had undergone both preoperative MRI
and PET/CT before radical surgery and lymphadenectomy.
The sensitivity, specificity, and accuracy of detecting LN
metastasis were 64.3%, 69.1%, and 67.5% for MRI and 28.6%,
83.6%, and 65.1% for PET/CT, respectively. The area under
the curve (AUC) for the MRI and PET/CT ROC curves were
0.667 and 0.561, respectively (p Z 0.013). MRI showed
significantly higher sensitivity for detecting metastatic LNs
than PET/CT (pZ 0.006).52 However, learning curve issues
result in serious variations between diagnostic efficacies.Benchmark examples of new MRI and PET
technologies and clinical endpoints in oncology
With the development of new technologies and new tar-
geting imaging drugs for use in MRI, PET, and single-photon
Table 1 Summary of the literature on the staging of locally advanced cervical cancer using CT/MRI and PET.
Authors Year Study Patient number/FIGO stage Purpose Gold standard Results
Yen et al23 2008 Prospective 70/untreated with
PLN or PALN
SUVmax in PET or PET/CT
as prognostic factor
5-year OS
5-yeay RFS
FIGO stage III/IV (p Z 0.008)
and SUVmax >3.3 at PALN (p Z 0.008)
are independent prognostic factors
Kidd et al24 2010 Retrospective 560/stage IAeIVB; before
primary surgery, RT/CCRT
LN staging by PET PLN and PALN:
treated with RT/CCRT:
unproven PLN and PALN:
treated with surgery
or ScLN: histological
evidence
HR for recurrence: PLN 2.40
(95% CI, 1.63e3.52), PALN 5.88
(95% CI, 3.80e9.09), and ScLN 30.27
(95% CI, 16.56e55.34)
Grigsby et al25 2001 Retrospective 101 before RT/CCRT LN staging, PET compared
with CT
PLN and PALN: unproven
SLN: histology evidence
CT: PLN-positive, 20%; PALN-positive, 7%
PET: PLN-positive, 67%; PALN-positive,
21%; SLN-positive, 8%
Yamashita26 2005 Retrospective 71/FIGO IIBeIIIB CT or MRI/before
CCRT or NACþRT
Histology or follow-up 15 CR/MRI-defined PALN-positive
5-year PFS: PALN-pos, 19.8%
5-year OS: PALN-pos 49.9%
Kim et al27 2009 Prospective 79/stage IBeIVA before
lymphadenectomy
PET/CT vs. PET/MR fusion Histology PET/CT vs. PET/MR fusion: Sv, 44.1%;
Sp, 93.9% vs. Sv,54.2%;
Sp, 92.7%; AUC:0.690
vs. 0.735, p Z 0.0259
Tsai et al28 2010 Prospective,
randomized
controlled trial
66 PETþ vs. 63 PET- Additional extrapelvic mets,
distant mets-free survival, OS
Image-guided biopsy
or follow-up
11% additional extrapelvic mets;
4-year OS: PETþ vs. PET-,
79% vs. 85%, p Z 0.65
Ramirez et al29 2011 Prospective 60/IB2-IVA
CT/MRI PALN negative
LN staging, PET compared with
laparoscopic extraperitoneal
PALN dissection
Surgery 14 true positive at PALN:
6 PETþ for PALN; 6 of 27 (22%) PLNþ,
PALN- by PET; 3 of 26 (12%) PLN-,
PALN- by PET
Kang et al30 2011 Prospective Training cohort, 62;
testing cohort, 54/IB2-IVA
before CCRT
Laparoscopic staging
PALN-negative PLN-positive
by PET
Distant failure FIGO stage > IIB and SCCAg > 2.4 ng/mL
for training cohort
PLN-positive by PET for distant failure:
100% Sv for training set and testing set
Chao et al31 2008 Prospective 47/untreated with
limited PALN, ScLN,
ILN metastasis
Clinical impact of
PET or PET/CT
Histology or
metabolic biopsy
44.7% positive impact
2-year OS: PALN, 50.9%;
ScLN, 24.7%
Qiu et al32 2007 Retrospective 33/stage IVB (ScLN mets) Clinical impact of PET or
PET/CT, prognostic factors
Histology SCC-Ag < 15 ng/mL (p Z 0.021),
staging including PET (p Z 0.006)
with better prognosis
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; PET, positron emission tomography; MRI, magnetic resonance imaging; CT, computed tomography; CCRT,
concurrent chemoradiation; PLN, pelvic lymph node; PALN, paraaortic lymph node; ScLN, supraclavicular lymph node; ILN, inguinal lymph node; SUV, standardized uptake value; mets,
metastasis; OS, overall survival; RFS, recurrence-free survival; Sv, sensitivity; Sp, specificity; NAC, neoadjuvant chemotherapy; HR: hazard ratio.
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Table 2 Summary of literature on using MRI and PET for treating early-stage cervical cancer or posttherapy surveillance.
Authors Year Study Patient number/FIGO stage Purpose Gold std Results
Mitchell et al6 2006 Prospective 208 stage IeII before surgery Diagnostic efficacy, patient-
based LN staging, depth,
tumor size MRI vs. CT
Histology by surgery MRI and CT inaccurate for
depth of invasion; uterine
body involvement AUC of ROC:
MRI vs. CT, 0.80 vs. 0.66, p Z 0.01)
Laiet al34 2004 Prospective 40 documented recurrence/
persistent potentially curable
Primary end point: %
improvement in restaging
Surgery or clinical
follow-up
55% modified treatment due
to PET; detecting metastatic
lesions: dual-phase PET vs.
MRI/CT (p < 0.0001)
Chang et al35 2004 Prospective 27/initial stage IeIV after
primary treatment
Restaging at SCC elevation
when CT/MRI (-)
Histology or
clinical follow-up
Sv, 94% (17/18); Sp 86%, (6/7);
PPV, 89% (17/19); NPV, 88% (7/8)
Lin et al36 2006 Prospective 26 curable re-recurrences
or unexplained SCCAg, CEA
elevation after salvage therapy
Clinical impact of using PET
in addition to CT/MRI
Biopsy/surgery or
clinical follow-up
12 (46.2%) Pts with positive impact
Poor prognosis for AD/ASC,
SCCAg > 4 ng/mL, site of
re-recurrence at central/pelvis
or distantþpelvis
36M survival 80% for score 0
Reinhart et al37 2001 Prospective 35 untreated Diagnostic efficacy, Patient-
based LN staging and LN
sites-based PET vs. MRI
Histology by surgery Patient-based PET vs. MRI,
Sv Z 0.91 vs. 0.73, p > 0.05
LN sites-based, PPV Z 0.90 vs.
0.64, p < 0.05
Goyal et al38 2010 Prospective 80/stage IB1eIIA
before surgery
PET to detect PLN mets Histology by surgery PET PLN detection: Sv, 58.3%;,
Sp, 92.8%; PPV, 77.7%; NPV, 83.8%;
postoperative RT reduced from 30%
to 12.5%
Chou et al40 2006 Prospective IA2-IIA
MRI LN(-)
n Z 60
PET to detect
PLN metastasis
Histology by surgery 16.7%, PLN mets; Sv, 10%; Sp, 94%;
PPV, 25%; NPV, 84%; FN
micrometastasis
0.50.5e76 mm
Ryu et al41 2003 Retrospective 249 posttherapy surveillance To detect asymptomatic
early recurrence
Histology or
clinical follow-up
80 pts with PET-positive:
PPV, 35%;Sv, 90.3%; Sp, 76.1%
Havrilesky et al42 2003 Retrospective 28 Detecting recurrence
when clinically suspicious
Histology or
clinical follow-up
Sv, 85.7%; Sp, 86.7%; PPV, 85.7%;
NPV, 86.7%
Hori et al47 2009 Prospective 31/stage IA1eIIB before surgery 1.5T vs. 3.0T MRI
detecting PLN mets
Histology by surgery No difference
Lin et al48 2008 Prospective 50/stage IeII before surgery 3T-MR size vs. sizeþADC Histology by surgery Combined size and ADC; Sv, 85%;
AUC 0.965 vs. size alone Sv, 25%;
AUC, 0.679; p Z 0.015
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; PET, positron emission tomography; MRI, magnetic resonance imaging; CT, computed tomography; CCRT,
concurrent chemoradiation; PLN, pelvic lymph node; OS, overall survival; SCCAg, squamous cell carcinoma antigen; ADC, apparent diffusion coefficient; mets, metastasis; Sv, sensitivity;
Sp, specificity; PPV, positive predictive value; NPV, negative predictive value; RT radiotherapy; M: months; FN: false negative; AD/ASC: adenocarcinoma and adenosquamous carcinoma.
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Molecular imaging in cervical cancer 417emission computed tomography (SPECT), these techniques
can provide sensitive and serial noninvasive information
regarding tumor characteristics. The merging of MRI and
PET technologies that can be applied to cervical cancer, as
summarized in Table 3.19,54e62
If we use breast cancer as an example, most clinical data
have been gathered on the visualization of general
processes such as the detection of tumor blood flow using
3T MRI contrast-enhanced dynamic studies, glucose
metabolism using 18F-FDG-PET, and DNA synthesis using 18F-
FLT.53 Increasingly, more breast cancer-specific targets are
being imaged such as the estrogen receptor (ER), growth
factors, and growth factor receptors. Imaging of the ER
using FES-PET has shown a good correlation between FESTable 3 Summary of the merging of MRI and PET technologies
New technologies Advantages
PET imaging of angiogenesis,
proliferation, apoptosis,
VEGF, EGFR, HER2,
somatostatin receptor
type 2 gene and type 5
gene (sstr-2/sstr-5)
Provide a variety of PET tracers
targeting specific molecular
entities allowing the noninvasive
measurement of biological
processes
Radioimmunoconjugates
for immuno-PET
High tumor-to-background tissue
contrast with high specificity,
tumor response
13C and 15N MRI Real time 13C, 15N images
using DNP or PHIP
Increased sensitivity with S/N ratio
enhancements >10,000-times
for 13C, 15N
Selective 13C, 15N metabolic imagin
PET/MR Higher resolution than CT,
no radiation dose, and provides
better functional information
Susceptibility-weighted
imaging (SWI)
Useful for emphasizing blood vesse
for example, vein- and iron-accum
lesions; clinical applicable for trau
tumor hypoxia, stroke, calcification
vessel density, and blood flow
Histogram analysis
of ADC for DWI MRI
As compared with average ADC,
histogram analysis of ADCs can offe
different calculation of DWI
NDA, new drug application; PET, positron emission tomography; MRI,
DWI, diffusion-weighted image; Fc, fragment crystallizable; DNP, dyn
[4,5-b]pyridine; S/N, signal to noise ratio; ADC, apparent diffusion couptake into tumors and ER density. Using 111In-trastuzumab
SPECT to image human epidermal growth factor receptor 2
(HER2) has shown that in most patients with metastatic
HER2 overexpression, more lesions are detected than with
conventional staging procedures. The PET tracer 89Zr-tras-
tuzumab has shown excellent, quantifiable, and specific
tumor uptake. The use of 111In-bevacizumab in SPECT and
89Zr-bevacizumab in PET imaging have been developed for
the imaging of vascular endothelial growth factor (VEGF) as
an angiogenic marker.54,55 Lastly, tracers for the EGFR, IGF-
1R, platelet-derived growth factor receptor (PDGFR)-
b receptors and the tumor necrosis factor (TGF)-b ligand
are under development.56 The use of radio-
immunoconjugates for immuno-PET offers high tumor-to-that can be applied to cervical cancer.
Disadvantages Example
Need repeated scans
due to the shifting of
signaling pathways during
treatment; no NDA
approved available so far
Breast cancer; can
help for treatment
planning in the
future54e57
Large decrease in
radiolabeled antibody
mediated by Fc receptor
Prostate cancer,
colorectal cancer56,58
g.
Instrumentation is expensive High-contrast imaging
of the lungs in clinical
trial on prostate
cancer patients19,59
The adverse effects of
scattered and accidental
gamma coincidences on the
quantitative accuracy of PET,
as well as artifacts caused
by the inherent crosstalk
between activity and
attenuation estimation
The disadvantages
can be reduced using
enhanced decay event
localization provided
by time-of-flight PET,
accurate correction
for accidental
coincidences, and a
reduced number of
unknown attenuation
coefficients60
ls,
ulated
ma,
s
Algorithms applied to
other tumor types may
not apply to cervical cancer
Clinically useful for
breast cancer at
baseline and after
2 courses of NAC
showed promise61
r
Algorithms applied to other
tumor types may not apply
to cervical cancer
Response to first
3 courses of
chemotherapy
correlated well with
histogram analysis of
ADC for DWI MRI in
ovarian cancer62
magnetic resonance imaging; NAC, neoadjuvant chemotherapy;
amic nuclear polarized; PHIP, 2-Amino-1-methyl-6-phenylimidazo
efficient.
418 C.-H. Lai et al.background tissue contrast in immuno-PET and can be used
as a tool for monitoring and quantifying tumor responses
with high specificity.57,58
The simultaneous reconstruction of activity and atten-
uation in PET/MR is attractive, yet there are downsides to
this technology, such as the fact that MR does not measure
photon attenuation and, thus, does not provide easy access
to this valuable information.59 A major challenge in cancer
biology is the monitoring and understanding of cancer
metabolism in vivo with the end goal of improving diagnosis
and treatment.60 Crucial metabolites may be present in low
concentrations and are, therefore, beyond the detection
limit of traditional MR methods. Hyperpolarized molecules
can be generated in aqueous solution and infused in vivo
where metabolism generates products that can be
imaged,60 which hold vast potential; however, we are still
a long way from developing clinical applications. Li et al61
used intrinsic susceptibility-weighted MR imaging in
patients with primary breast cancer to assess the rela-
tionship between the baseline transverse relaxation rate
(R2*), changes in the T2* relaxivity (6 R2*), and the
response to neoadjuvant chemotherapy (NAC). Their results
suggest that an increase in R2* after two cycles of NAC
correlates with the pathologic response and that therapy-
induced uncoupling of the relationship between R2* and
relative blood volume (rBV) and relative blood flow (rBF) is
consistent with the responding tumors becoming hypoxic
shortly after beginning treatment.
Aprospective studyevaluated apparentADChistograms in
order to assess the chemotherapeutic response of patients
with metastatic ovarian or primary peritoneal cancer,
demonstrating that all ADCs increased after the first and
third cycles (p < 0.001) while skew and kurtosis decreased
after the third cycle (p < 0.001 and 0.006, respectively) in
responders but not in nonresponders.62 Chen et al used 3T
MRI to assess the response to NAC in correlation with the
molecular markers HER2, ER, and Ki67. The mean MR
imaging-pathologic size discrepancy was 0.5 cm  0.9 for
HER2-positive cancer and 2.3 cm  3.5 for HER2-negative
cancer (p Z 0.009). In the HER2-negative group, the size
discrepancy was smaller for hormone receptor-negative
cancers than for hormone receptor-positive cancers
(1.0 cm  1.1 vs. 3.0 cm  4.0, pZ 0.04).63
Cost-effective analyses should be encouraged as an
endpoint in research on the use of new diagnostic tools,
such as new PET and MRI technologies. Comparisons of
alternative or threshold values will lead to the identifica-
tion of the most efficient ways to maximize health at the
population level.64 FDG-PET has been used to evaluate
patients with head and neck cancer using distant metastasis
as the risk factors and has been determined to be cost-
effective.65 FDG-PET demonstrated 95.9% accuracy for
restaging patients with Hodgkin’s lymphoma after first-line
therapy, and the ICER was -$3,268 US dollars.66Conclusion
18F-FDG is still the only tracer approved for routine use.
Currently, several novel targeting PET compounds have
been developed for oncological studies, either for clinical
use or at different stages of clinical evaluation. The resultsof using nanoparticle contrast media-enhanced MRI, high-
Tesla machines, diffusion-weighted imaging without
contrast, and spectroscopy are promising. The role of using
molecular imaging (e.g., new MRI and PET technologies) as
an early predictor of response to treatment is an emerging
utility that requires more clinical investigations. Cost-
effective analysis should be encouraged as an endpoint in
research regarding the use of new diagnostic tools, such as
new PET and MRI technologies.
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